newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

  • AEON Biopharma announced the first closing of its PIPE on November 18, 2025, generating approximately $1.79 million in proceeds.
  • The FDA rescheduled AEON's BPD Type 2a meeting from November 19, 2025, to January 21, 2026, to review analytical development plans.
  • The second PIPE closing remains subject to stockholder approval & other transaction conditions.
  • Proceeds from the first closing & anticipated funds from the second closing aim to accelerate ABP-450 biosimilar development by up to six months.
  • ABP-450 is a prabotulinumtoxinA biosimilar candidate targeting the U.S. therapeutic neurotoxin market against BOTOX.
  • The product is currently approved as a biosimilar in India, Mexico, & the Philippines, with manufacturing occurring in a facility approved by the FDA, Health Canada, & the EMA.